Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects.

Buckley CE, Marguerie A, Roach AG, Goldsmith P, Fleming A, Alderton WK, Franklin RJ.

Neuropharmacology. 2010 Sep;59(3):149-59. doi: 10.1016/j.neuropharm.2010.04.014. Epub 2010 May 5.

PMID:
20450924
2.

Temporal dynamics of myelination in the zebrafish spinal cord.

Buckley CE, Marguerie A, Alderton WK, Franklin RJ.

Glia. 2010 May;58(7):802-12. doi: 10.1002/glia.20964.

PMID:
20140960
3.

Zebrafish: An in vivo model for the study of neurological diseases.

Best JD, Alderton WK.

Neuropsychiatr Dis Treat. 2008 Jun;4(3):567-76.

4.

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ.

J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.

PMID:
18754654
5.

Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery.

Barros TP, Alderton WK, Reynolds HM, Roach AG, Berghmans S.

Br J Pharmacol. 2008 Aug;154(7):1400-13. doi: 10.1038/bjp.2008.249. Epub 2008 Jun 16. Review.

6.

Validation of the use of zebrafish larvae in visual safety assessment.

Richards FM, Alderton WK, Kimber GM, Liu Z, Strang I, Redfern WS, Valentin JP, Winter MJ, Hutchinson TH.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):50-8. doi: 10.1016/j.vascn.2008.04.002. Epub 2008 May 2.

PMID:
18541443
7.

GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo.

Alderton WK, Angell AD, Craig C, Dawson J, Garvey E, Moncada S, Monkhouse J, Rees D, Russell LJ, Russell RJ, Schwartz S, Waslidge N, Knowles RG.

Br J Pharmacol. 2005 Jun;145(3):301-12.

8.

Kinetics of CO binding to the haem domain of murine inducible nitric oxide synthase: differential effects of haem domain ligands.

Stevenson TH, Gutierrez AF, Alderton WK, Lian L, Scrutton NS.

Biochem J. 2001 Aug 15;358(Pt 1):201-8.

9.

Nitric oxide synthases: structure, function and inhibition.

Alderton WK, Cooper CE, Knowles RG.

Biochem J. 2001 Aug 1;357(Pt 3):593-615. Review.

10.
12.
13.

Affinity labeling of recombinant ricin A chain with Procion blue MX-R.

Alderton WK, Thatcher D, Lowe CR.

Eur J Biochem. 1995 Nov 1;233(3):880-5.

14.

Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses.

Lowe DM, Alderton WK, Ellis MR, Parmar V, Miller WH, Roberts GB, Fyfe JA, Gaillard R, Ertl P, Snowden W, et al.

Antimicrob Agents Chemother. 1995 Aug;39(8):1802-8.

15.

Designer dyes: 'biomimetic' ligands for the purification of pharmaceutical proteins by affinity chromatography.

Lowe CR, Burton SJ, Burton NP, Alderton WK, Pitts JM, Thomas JA.

Trends Biotechnol. 1992 Dec;10(12):442-8. Review.

PMID:
1369134

Supplemental Content

Loading ...
Support Center